Karen M. Anderson
CIK 1762176 · Chief People Officer · last filed 2026-06-24
Karen M. Anderson is a Chief People Officer who has filed 38 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$17.1M, making them a net seller over the disclosed history. 9 Form 144 notices of planned sales are also on file; the latest, for Centessa Pharmaceuticals plc on Mar 26, 2026, lists the filer as an officer. 7 sales listed on those notices, worth $6.2M in all, have no matching Form 4.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CNTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM
CHESHIRE, X0 WA14 2DT
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief People Officer | 0 | $40.50 | $0 | -$11.24M | 13 | 2026-06-24 |
| Mimecast Ltd (MIME) Delisted | Chief Human Resources Officer | 8,649 | $79.92 | $691.2K | -$5.89M | 15 | 2022-04-04 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | −62,085 | $0 | EDGAR |
| 2026-03-27 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Nov 12, 2025 |
— | -$908.4K | EDGAR |
| 2026-03-26 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Mar 26, 2026 · 10b5-1 plan No sale on file |
−41,076 | -$1.16M | EDGAR |
| 2026-03-18 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Nov 12, 2025 |
— | -$1.81M | EDGAR |
| 2026-03-17 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Mar 17, 2026 · 10b5-1 plan Sold: listed on the Mar 26, 2026 notice |
−10,043 | -$281.0K | EDGAR |
| 2026-03-16 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Mar 16, 2026 · 10b5-1 plan Sold: listed on the Mar 17, 2026 notice |
−64,768 | -$1.83M | EDGAR |
| 2026-03-16 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Nov 12, 2025 |
−10,631 | -$2.71M | EDGAR |
| 2026-03-13 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Mar 13, 2026 · 10b5-1 plan Sold: listed on the Mar 16, 2026 notice |
−120,029 | -$3.10M | EDGAR |
| 2026-03-13 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Nov 12, 2025 |
−10,631 | -$2.71M | EDGAR |
| 2026-02-03 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | +18,394 | -$260.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
7 sales · $6.23M| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2026-03-17 | Centessa Pharmaceuticals plc | 10,043 | $282.2K | $28.10 | 2026-03-26 |
| 2026-03-16 | Centessa Pharmaceuticals plc | 64,768 | $1.83M | $28.21 | 2026-03-17 |
| 2026-03-13 | Centessa Pharmaceuticals plc | 120,029 | $3.15M | $26.25 | 2026-03-16 |
| 2025-02-07 | Centessa Pharmaceuticals plc | 30,526 | $580.8K | $19.03 | 2025-02-10 |
| 2025-02-03 | Centessa Pharmaceuticals plc | 6,471 | $109.1K | $16.86 | 2025-02-07 |
| 2024-12-17 | Centessa Pharmaceuticals plc | 10,624 | $184.0K | $17.32 | 2025-02-03 |
| 2024-12-13 | Centessa Pharmaceuticals plc | 5,876 | $100.0K | $17.01 | 2025-02-03 |